130 filings
Page 5 of 7
6-K
yvg 21mev7
28 Sep 20
Mereo BioPharma Announces Changes to Board of Directors
8:08am
6-K
5tihpvkdom
24 Sep 20
Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta
8:48am
6-K
lsz2j
4 Sep 20
Current report (foreign)
7:00am
6-K
s9t5ahk0
25 Aug 20
Mereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease
11:14am
6-K
3rukoy1rw6qf6 cs
3 Aug 20
Current report (foreign)
9:15am
6-K
ez72e3sdw
30 Jun 20
Result of Annual General Meeting
4:07pm
6-K
4lstkc
16 Jun 20
Current report (foreign)
4:13pm
6-K
ii1u6 dtlc2df
9 Jun 20
Publication of Circular and Notice of General Meeting
4:15pm
6-K
k2p5zafo
5 Jun 20
Mereo BioPharma Announces Completion of $70 Million Private Placement
12:00am
6-K
x0sa2z62
27 May 20
Notice of Annual General Meeting
7:37am
6-K
9czutze088 86pupb
22 May 20
Annual General Meeting
9:31am
6-K
mpns5cyuq37bap
28 Apr 20
Current report (foreign)
4:10pm
6-K
jdi8 jrk0z806g3sl
27 Mar 20
Business Update and Directorate Change
9:09am
6-K
47r7b4vtc
28 Feb 20
Current report (foreign)
9:46am
6-K
36k8nyrz
21 Feb 20
Current report (foreign)
4:30pm
6-K
6ovyhyocwk866
19 Feb 20
Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor
9:32am
6-K
ka9zrtv 2nwp9
18 Feb 20
Current report (foreign)
11:43am
6-K
9qoxv9 5t03xgd2udp
12 Feb 20
Mereo Biopharma Announces Update on Distribution Related to Contingent Value Rights Following Recent Oncologie Licensing Agreement for Navicixizumab
9:48am
6-K
08s88x5j 09dzj4
10 Feb 20
Current report (foreign)
7:20am
6-K
m8xrfmy188t8cs8mq5
14 Jan 20
Current report (foreign)
8:40am